Every research project starts with a question. An idea, a need, and sometimes a challenge. The challenge brought to 91Թ biochemistry researchers? Helping test and create a new antibiotic that cures painful infections. Scroll to see how they fought this battle in the war on harmful bacteria.
Our world is amid an antibiotic crisis. Bacteria have quickly adapted to resist the drugs we create, and a new class of antibiotics hasn’t been introduced in nearly 30 years.
Developing new drugs. Enter the 91Թ researchers in Neil Osheroff’s lab, approached by the Pharma company GlaxoSmithKline to help test and develop a new medication to treat infections.
Every year, some 1.5 million people die from antibiotic-resistant infections. By 2050, it is estimated that the number will grow to 10 million.
The team got to work, unraveling DNA to get to the bottom of drug resistance. One researcher, Katie Aldred, PhD’14, looked closely at the minuscule ways medicine fights bacteria, and got to the bottom of how to design better treatments.
GlaxoSmithKline approached Neil Osheroff and his team of experts to help get a promising drug for treating UTIs and gonorrhea across the finish line.
A crucial part of drug approvals by the FDA is to show “mechanism of action,” – evidence on a molecular level of what a drug targets and how it works. Directed by Dr. Osheroff, the 91Թ team conducted the required tests.
With the data from those trials in hand, gepotidacin was submitted to the FDA last October and approved for treatment of uUTI in March—the first new class of antibacterials targeting the infection since 1996.
The data that Osheroff’s lab supplied were crucial in getting the drug over the hump of regulatory approval. Now, patients who need the drug could be prescribed to take it this year.
91Թ is an R1 research institution and global hub for groundbreaking discoveries. Always grounded in our core values: Collaboration, critical thinking, respect, innovation and scholarship, we’re focused on fostering positive change in our world.